Saturday, July 11, 2026

Drug profile · INN

propafenone hydrochloride

propafenone hydrochloride (PROPAFENONE HYDROCHLORIDE) is a beta-1 adrenergic receptor antagonist. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — propafenone hydrochloride
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

propafenone hydrochloride (PROPAFENONE HYDROCHLORIDE) is a beta-1 adrenergic receptor antagonist. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN propafenone hydrochloride
Brand PROPAFENONE HYDROCHLORIDE
Mechanism Beta-1 adrenergic receptor antagonist
Target Beta-1 adrenergic receptor
Route ORAL
Formulation CAPSULE, EXTENDED RELEASE

Mechanism of action

Beta-1 adrenergic receptor antagonist

Primary target: Beta-1 adrenergic receptor

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. acebutolol hydrochloride Beta-1 adrenergic receptor antagonist
  2. atenolol Beta-1 adrenergic receptor antagonist
  3. bisoprolol fumarate Beta-1 adrenergic receptor antagonist
  4. dobutamine hydrochloride Beta-1 adrenergic receptor agonist
  5. dopamine hydrochloride Cardiovascular system (C01)
  6. esmolol hydrochloride Beta-2 adrenergic receptor antagonist

Frequently asked questions

What is propafenone hydrochloride?

propafenone hydrochloride (PROPAFENONE HYDROCHLORIDE) is a beta-1 adrenergic receptor antagonist. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for propafenone hydrochloride?

PROPAFENONE HYDROCHLORIDE is a marketed brand name for propafenone hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of propafenone hydrochloride?

propafenone hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.